SATISFACTION AND REDUCTION IN DIABETES BURDEN WITH PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) IN INDIVIDUALS WITH TYPE 1 DIABETES (T1D)
- Laurel H. Messer, United States of America
- Laurel H. Messer, United States of America
- Kristen Campbell, United States of America
- Gregory P. Forlenza, United States of America
Abstract
Background and Aims
Basal-IQ (Tandem Diabetes) is a PLGS system that demonstrated high user satisfaction in clinical trials. It is unknown whether users experience sustained satisfaction and reduced diabetes burden in the real-world.
Methods
Participants with T1D completed the Diabetes Burden and Device Assessment (DBDA) 11 item, 10 point Likert scale survey prior to Basal-IQ use, and at 2, 4, 6 months after start. The DBDA includes a Satisfaction factor (trust, ease of use, etc.) and Diabetes Burden factor (hypoglycemia fear, poor sleep, etc.). Linear regression tested for change in scores from baseline to midpoint (2 or 4 months) and midpoint to 6 months, adjusted for baseline covariates.
Results
541 participants (mean±sd age 36.7±16.9 years, HbA1c 7.2±1.1%) completed surveys: 300 Tandem pump users, 159 other pump users, 82 multiple daily injections (MDI) users. Both factors demonstrated adequate internal consistency (alpha = 0.70-0.86). From baseline to midpoint, satisfaction significantly increased in previous MDI users [mean 2.32 points (Bonferroni adjusted CI: 1.8, 2.84), p<0.001] and non-Tandem pump users [1.13 points (CI: 0.64, 1.62), p<0.001], with no increase in Tandem users (p=1). The satisfaction sustained at 6 months with no significant change from midpoint (Figure 1A). From baseline to midpoint, Diabetes Burden was significantly reduced for previous MDI users [-1.60 points (CI: -2.18, -1.02), p<0.001], non-Tandem pump users [-0.91 ( -1.46, -0.36), p<0.001] and Tandem pump users [-0.89 (-1.4, -0.37), p<0.001], and sustained through 6 months (Figure 1B). 
Conclusions
In the real-world, Basal-IQ users with T1D reported high satisfaction and decreased diabetes burden over previous insulin modality.